A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Phase 2
Completed
NCT03771898
| Condition | Metachromatic Leukodystrophy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Shire |
|---|
| Status | Completed |
|---|
| Enrollment | 36 participants |
|---|
| Interventions | SHP611 |
|---|
| Start date | May 13, 2019 |
|---|
| Completion date | Mar 8, 2023 |
|---|
| Results posted | Jun 6, 2024 |
|---|
Summary
The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; IT) prolongs the time for children with Metachromatic Leukodystrophy (MLD) to retain the ability to move from place to place. Other aims of the study are to determine the effects of intrathecal administration of SHP611 on movement and speech functions and to learn how well SHP611 injected in the spinal fluid that surrounds the brain and spinal cord is tolerated. Study participants will receive SHP611 for about 2 years with the possibility of an extended treatment period.
Percent Probability of Free of Loss of Locomotion in the Last Time Interval Up to 2 Years (Week 106) Based on GMFC-MLD for SHP611 Group A and GLIA-MLD Matched External Control
Baseline up to Week 106 · percent probability
| Group A, SHP611 | 7.1 percent probability |
|---|
| GLIA-MLD Matched External Control for Group A | 9.4 percent probability |
|---|
| p-value | =0.585 |
|---|
| Difference in survival probability (%) | -2.2 (95% CI -22.2–17.7) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.